Reports on Obesity, Fitness and Wellness Findings from University of Miami Provide New Insights (Btk Inhibitors: Past, Present, and Future).

Předmět:	BRUTON tyrosine kinase B cell lymphoma CHRONIC lymphocytic leukemia CHARITABLE foundations ELECTRONIC records
Zdroj:	Genomics & Genetics Weekly; 9/13/2024, p1455-1455, 1p
Abstrakt:	A recent report from the University of Miami discusses the development and future prospects of Bruton's tyrosine kinase (BTK) inhibitors in the treatment of B cell lymphomas and autoimmune diseases. The report highlights the success of the first-in-class BTK inhibitor ibrutinib and the challenges of resistance mutations. It also mentions the approval of the noncovalent BTK inhibitor pirtobrutinib for relapsed and refractory chronic lymphocytic leukemia (CLL). The research concludes that further advancements in BTK inhibitor development are expected. This information is based on a peer-reviewed article published in Trends in Pharmacological Sciences. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu